Most consumer categories remained under pressure in 3Q and recovery seems more gradual for the sector. HUL's management of the situation is far superior to peers. Home Care and F&R are driving both revenue and profitability. BPC is seeing various challenges as BPC volume market degrew by 2% in 3Q. GSK's acquisition is running behind schedule and is expected to be integrated by Mar-20 (vs. Dec-19 earlier). We maintain our NEUTRAL rating as we don't see any near-term triggers for re-rating the stock. HULs 3QFY20 show was respectable amidst challenges of slowdown. Co maintains a cautious near term outlook and is hopeful for gradual recovery in rural demand. Net revenue growth of 4% with 5% UVG was better than many consumer companies despite large scale. Marico/Colgate/Dabur posted domestic volume growth of -1/2.3/5.6%. We are admirers of HULs superior capabilities in managing tough times. We value HUL at 45x on Dec-21 EPS with TP of Rs 1,988. Maintain NEUTRAL.